You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

glucagon-like peptide-1 (GLP-1)

Showing 26 - 50 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Type 2 Diabetes, Peripheral Arterial Disease Trial in Napoli (Liraglutide, Control)

Recruiting
  • Type 2 Diabetes
  • Peripheral Arterial Disease
  • Napoli, Italy
    Unit of Endocrinology and Metabolic Diseases and Unit of Diabete
Jun 9, 2021

Effects of Glucagon-like-Peptide-1 Analogues on Sexuality

Recruiting
  • Sexual Desire
    • Basel, Switzerland
      University Hospital Basel, Endocrinology, Diabetes and Metabolis
    Nov 28, 2022

    Type 2 Diabetes Trial in Bronx (glucagon like peptide-1, glucose control)

    Completed
    • Type 2 Diabetes
    • glucagon like peptide-1
    • glucose control
    • Bronx, New York
      Albert Einstein College of Medicinie
    Apr 21, 2021

    Metabolic Disturbance, Schizophrenia, Type 2 Diabetes Trial in Copenhagen (Semaglutide, 1.34 mg/mL, Semaglutide-)

    Not yet recruiting
    • Metabolic Disturbance
    • +5 more
    • Semaglutide, 1.34 mg/mL
    • Semaglutide-placebo
    • Copenhagen, Denmark
      Psychiatric Center Copenhagen, Rigshospitalet
    Jun 30, 2021

    GLP-1 Concentration Trial in Bath (Dose response of Capolac®)

    Completed
    • GLP-1 Concentration
    • Dose response of Capolac®
    • Bath, Somerset, United Kingdom
      Department for Health, University of Bath
    Apr 27, 2021

    Type1 Diabetes Trial in Baltimore (Glucagon-like peptide-1, Placebos)

    Recruiting
    • Type1 Diabetes Mellitus
    • Glucagon-like peptide-1
    • Placebos
    • Baltimore, Maryland
      University of Maryland
    Apr 8, 2022

    Type 2 Diabetes, Coronary Artery Disease Trial in Athens (Liraglutide, Metformin)

    Completed
    Has Results
    • Type 2 Diabetes Mellitus
    • Coronary Artery Disease
    • Athens, Attiki, Greece
      ''Attikon'' University General Hospital
    Mar 3, 2021

    Coronary Disease, Shock, Cardiogenic, Renal Failure Trial in Copenhagen (Byetta (Lilly, Exenatide), Conoxia (AGA, oxygen), 20%

    Recruiting
    • Coronary Disease
    • +5 more
    • Byetta (Lilly, Exenatide)
    • +2 more
    • Copenhagen, Denmark
      Rigshospitalet - Copenhagen University Hospital
    Apr 15, 2021

    Healthy Trial in Oxford (25 g Nutralys Pea Protein, 50 g Nutralys S85 Plus., 50 g Glucose)

    Completed
    • Healthy
    • 25 g Nutralys Pea Protein
    • +2 more
    • Oxford, United Kingdom
      Oxford Brookes Centre for Nutrition and Health
    Oct 29, 2020

    Stroke, Stroke, Acute, Stroke, Ischemic Trial in Linyi, Hong Kong (Semaglutide)

    Recruiting
    • Stroke
    • +3 more
    • Linyi, Shangdong, China
    • +1 more
    Jun 24, 2023

    Diabetes, Diabetes, Type 2 Trial in Nijmegen (111In-DTPA-exendin-4, IRDye800CW-exendin-4)

    Unknown status
    • Diabetes Mellitus
    • Diabetes Mellitus, Type 2
    • Nijmegen, Gelderland, Netherlands
      Radboud University Medical Center
    Jan 28, 2021

    Alcohol Dependence, in Remission, Addiction, Alcohol Trial in Copenhagen (Exenatide 2 MG Injection, BD PosiFlush (saline))

    Completed
    • Alcohol Dependence, in Remission
    • Addiction, Alcohol
    • Exenatide 2 MG Injection
    • BD PosiFlush (saline)
    • Copenhagen, Frederiksberg, Denmark
      Novavì ambulatorierne
    Jun 3, 2021

    Type 2 Diabetes Trial in Japan (Tofogliflozin, GLP-1 analogue)

    Completed
    • Type 2 Diabetes Mellitus
    • Atsuta-ku, Aichi, Japan
    • +10 more
    Nov 15, 2020

    Type 2 Diabetes Trial in Copenhagen (Endurance exercise training, Semaglutide)

    Recruiting
    • Type 2 Diabetes
    • Copenhagen, Denmark
      Xlab, Center for Healthy Aging, Department of Biomedical Science
    Feb 8, 2021

    Sexual Functioning Trial in Basel (Dulaglutide, Placebo)

    Recruiting
    • Sexual Functioning
    • Basel, Switzerland
      University Hospital Basel, Endocrinology, Diabetes and Metabolis
    Mar 3, 2022

    Polycystic Ovary Syndrome, Obesity Trial in Baton Rouge (Exenatide once weekly (EQW ), Dapagliflozin (DAPA), EQW plus DAPA)

    Completed
    Has Results
    • Polycystic Ovary Syndrome
    • Obesity
    • Exenatide once weekly (EQW )
    • +4 more
    • Baton Rouge, Louisiana
      Woman's Hospital
    Jan 9, 2021

    Antrum Size, Glucagon-like Peptide 1 Levels and Glycemic Control

    Completed
    • Adolescent Obesity
    • Laparoscopic sleeve gastrectomy
    • (no location specified)
    May 11, 2020

    Blood Flow Trial in Copenhagen (GIPR antagonist / study tool, GLP-2R antagonist / study tool, Placebo)

    Recruiting
    • Blood Flow
    • GIPR antagonist / study tool
    • +2 more
    • Copenhagen, Denmark
      Rigshospitalet
    Nov 2, 2022

    Obesity Trial in Mansourah, Mansoura (Liraglutide)

    Recruiting
    • Obesity
    • Mansourah, Dakhlia, Egypt
    • +1 more
    Feb 24, 2022

    Kidney Transplant Recipients Trial in Toronto (Dapagliflozin 10 MG, Semaglutide, 1.0 mg/mL)

    Not yet recruiting
    • Kidney Transplant Recipients
    • Dapagliflozin 10 MG
    • Semaglutide, 1.0 mg/mL
    • Toronto, Ontario, Canada
      Toronto General Hospital
    Jul 6, 2023

    Type 2 Diabetes, Obesity Trial in Cambridge (0.9% Sodium-chloride, Exenatide (50ng/min for 30 minutes loading followed by

    Recruiting
    • Type 2 Diabetes
    • Obesity
    • 0.9% Sodium-chloride
    • +3 more
    • Cambridge, Cambridgeshire, United Kingdom
      Cambridge University Hospitals NHS Foundation Trust and The Univ
    Jan 18, 2022

    Wolfram Syndrome Trial (Tirzepatide)

    Not yet recruiting
    • Wolfram Syndrome
    • (no location specified)
    Dec 12, 2022

    Healthy Volunteers Trial in Knoxville (SHP681, Placebo)

    Completed
    Has Results
    • Healthy Volunteers
    • Knoxville, Tennessee
      New Orleans Center for Clinical Research
    Feb 8, 2021

    Type 2 Diabetes, PreDiabetes Trial in Johor Bahru (Sitagliptin)

    Completed
    • Type 2 Diabetes Mellitus
    • PreDiabetes
    • Johor Bahru, Johor, Malaysia
      Hospital Sultan Ismail
    Mar 13, 2022

    Asthma Trial in Nashville (Semaglutide Pen Injector 2.4mg weekly, Placebo)

    Not yet recruiting
    • Asthma
    • Semaglutide Pen Injector 2.4mg weekly
    • Placebo
    • Nashville, Tennessee
      Vanderbilt University Medical Center
    Jun 22, 2022